HYBRID EVENT: You can participate in person at Baltimore, Maryland, USA or Virtually from your home or work.
Yuko Harada, Speaker at Oncology Conferences
Kawasaki Municipal Ida Hospital, Japan

Abstract:

As chemotherapy has advanced in recent years, 10-year survival of breast cancer patients has become as high as 79.3% in Japan. However, the prognosis of patients may be hampered by cardiotoxicity of anti-cancer treatment. It is known that Anthracyclines and Trastuzumab cause some damages to the patients’ hearts even though they are very effective for breast cancer treatment. 

Biography:

Yuko Harada, M.D., received her M.D. degree from the Keio University School of Medicine. She is currently Vice Director of the Department of Cardiology at Kawasaki Municipal Ida Hospital. From 2018 to 2020 she was Division Head of General Internal Medicine at Yamato Tokushukai Hospital.  From 2014 to 2018 she was Director of the Department of Internal Medicine at Shin-yurigaoka General Hospital.  She received the Chairman’s Award from the Japan Endocrinology Association for her life-saving work on thyroid storm.  She has authored numerous pioneering research and medical papers in the fields of Internal Medicine, Cardiology, and Radiology.

Watsapp